Kamala Harris

Joe Biden

Dean Phillips

Marianne Williamson

Donald Trump

Vivek Ramaswamy

Nikki Haley

Ron DeSantis

Cornel West

Robert F. Kennedy

2024 United States Presidential Election

The Food and Drug Administration (FDA) said it will reconsider its decision to remove Eli Lilly’s blockbuster weight loss and diabetes drug from its official shortage list and allow compounding pharmacies to continue selling their own versions. 



tag:reuters.com,2023:binary_RC26V4AIDH6R-BASEIMAGE

Reuters

United Kingdom

U.S. FDA to reconsider decision barring compounded versions of Lilly weight loss drug

The agency said it would now allow compounding pharmacies and facilities to provide the drugs while it reviews if there is a shortage of their active ingredient.

Ad Fontes Media

All Sides

Media Bias/Fact Check

The Woodbridge Company

The Food and Drug Administration (FDA) said it will reconsider its decision to remove Eli Lilly’s blockbuster weight loss and diabetes drug from its official shortage list and allow compounding pharmacies to continue selling their own versions.  A federal court in Texas on Friday granted the FDA’s unopposed motion to stay litigation over the drug’s…

The Hill

Nexstar Media Group

Washington

District of Columbia

United States

FDA will reconsider decision barring copycat versions of Lilly weight loss drug

The FDA said in a court filing late Friday that it would allow pharmacists to continue making compounded versions of tirzepatide as it reconsiders whether the drug is in shortage.

NBC News

Roberts family

Compounding pharmacies can resume making tirzepatide as FDA reconsiders shortage

By Brendan Pierson (Reuters) -The U.S. Food and Drug Administration on Friday agreed to reconsider a decision it made last month to bar drug compounders from selling their own versions of Eli Lilly’s blockbuster weight loss and diabetes drugs. The agency said in a court filing it would now allow compounding pharmacies and facilities to keep providing the drugs while it reviews whether there is a shortage of their active ingredient. The compoundi…

WTVB

Midwest Communications

US FDA to reconsider decision barring compounded versions of Lilly weight loss drug

The Food and Drug Administration (FDA) said it will reconsider its decision to remove Eli Lilly’s blockbuster weight loss and diabetes drug from its official shortage list and allow compounding pharmacies to continue selling their own versions.  A federal court in Texas on Friday granted the FDA’s unopposed motion to stay litigation over the drug’s removal from shortage.   In a court filing late Friday, the FDA said it wouldn’t pursue regulatory…

WGN 9

Tribune Media

Chicago

Cook County

Illinois

WANE-TV

Fort Wayne

Allen County

Indiana

NWAHOMEPAGE

The decision, disclosed in a court filing, will allow certain compounders to continue making copies of tirzepatide for the time being.

STAT

The Boston Globe

Boston

Suffolk County

Massachusetts

In stark reversal, FDA to reconsider removal of Eli Lilly weight loss drug from shortage list

SecularTimes

The Food and Drug Administration said in a court filing late Friday that it would allow pharmacists to continue making compounded versions of tirzepatide — the active ingredient in Eli Lilly’s diabetes and weight loss drugs Mounjaro and Zepbound — while it reconsiders its decision to remove the drug from its nationwide shortage list. The surprise move is a major victory for compounding pharmacists and patients who were furious with the FDA after…

mnnofa.com

Compounding pharmacies can resume making tirzepatide as FDA reconsiders shortage – Mnnofa

FDA will reconsider decision barring copycat versions of Lilly weight loss drug

Coverage Details

Bias Distribution

Ownership

Similar News Topics

Similar News Topics